In BRAF-mutant PTC, however, neither lymph node metastasis (HR: 1.34, 95%CI: 0.35–5.09) nor HT (HR: 0.69, 95%CI: 0.16–3.03) remained independent predictors of recurrence. This evidence concerns the gene BRAF and metastatic malignant neoplasm in the lymph nodes.